Skip to main content

BaseLaunch up to a solid Phase II start

| News

BaseLaunch up to a solid Phase II start


BaseLaunch has officially started Phase II of its accelerator program, and four startups are receiving grants ranging from 120,000 to 250,000 Swiss francs. This non-dilutive funding will help them to reach key value inflection milestones to advance their scientific hypothesis and further build their ventures, while learning and benefiting from the Basel life sciences ecosystem. Furthermore, two startups will gain access to the ready-to-use laboratory and office space, both free of charge, at the Switzerland Innovation Park Basel Area.

BaseLaunch Teams (img: Mathias Mangold)

BaseLaunch successfully ran its first acceleration phase from September to November 2017. During these three months, 11 healthcare ventures worked together with experienced advisors to further define and advance their projects. Activities included firming up their respective business opportunities, ensuring focus on the essential tasks to bring forward their ventures, but also identifying key risks and corresponding actions to address them. Furthermore, the projects benefited from accessing valuable industry knowledge and market know-how from seasoned professionals representing the BaseLaunch healthcare partners: Johnson & Johnson Innovation, Novartis Venture Fund, Pfizer, Roche and Roivant Sciences.

Trudi Haemmerli, who presides over the selection committee of BaseLaunch, explains which parameters were prioritized: “We focused on innovation, the quality of the people and the scientific evidence that was presented so far. Also we took in consideration if and how the project could benefit from the Basel life sciences cluster.” The selected projects are strongly committed to explore the Basel region and the talent the ecosystem has to offer, by having operations in the region.

BaseLaunch will support six projects in Phase II of the program: Anaveon, Tepthera, TheraNASH and T3 Pharmaceuticals will receive grants ranging from 120,000 to 250,000 Swiss francs. Furthermore, Polyneuron Pharmaceuticals and Versameb will gain access to the ready-to-use laboratory and office space, both free of charge, at the Switzerland Innovation Park Basel Area.


BaseLaunch started in 2017 to accelerate the development of promising and innovative healthcare startups benefiting from the dynamic life sciences cluster of the Basel region. During the first cycle, more than 100 projects from more than 30 countries applied, reaffirming the strong unmet need that BaseLaunch addresses. The healthcare partners played an active role by giving key strategic feedback to the projects. “We provided a highly customized program making the needs of the entrepreneurs and their ventures our key priorities,” says Alethia de León, Managing Director of BaseLaunch. “Now we are looking forward to helping the selected companies to move further in the venture creation process and to attract further investments.”

Applications for the BaseLaunch cycle of 2018 are now open. For more information on companies selected for Phase II and the application process, visit

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.